DIAGNOSIS:
ABP WITH RISK OF ANTIBIOTIC-RESISTANT 1st line: Ertapenem 1g IV qd OR Meropenem 1g IV q8h (for
PATHOGENS
ABP WITH RISK OF STD
ACUTE BACTERIAL ARTHRITIS
ACUTE BACTERIAL EXACERBATION
(BRONCHIECTASIS)
ACUTE BACTERIAL EXACERBATION OF
CHRONIC BRONCHITIS (ABECB), ADULTS
ACUTE BACTERIAL MENINGITIS DUE TO
ANATOMIC DEFECTS, NEUROSURGICAL
COMPLICATIONS AND OPEN HEAD
TRAUMA
ACUTE BACTERIAL PROSTATITIS (ABP)
WITHOUT RISK OF STD
ACUTE BACTERIAL RHINOSINUSITIS
(ABRS)
ACUTE BACTERIAL SKIN AND SKIN
STRUCTURE INFECTIONS (ABSSSI)
DURATION OF TREATMENT:
Pseudomonas)
2nd line: Cefepime 2g IV q12h
Comments: Consider a 4-week regimen.
Preferred Regimen:
Ceftriaxone 250mg IM x 1 dose PLUS
Doxycycline 100mg bid or Azithromycin 500 mg PO qd
DOT: 2 weeks
Consider as an emergency. Collect blood and joint fluid for culture before
starting empiric antibiotic treatment. Empiric antibiotic choices should be
based on joint fluid Gram stain. Adjust treatment based on
culture/sensitivity results. Joint drainage is essential.
A: Levofloxacin 500mg PO q24h x 7-10d
Prevention of exacerbation:
Erythromycin 500mg PO bid OR Azithromycin 250mg q24h x 1 year
Treatment of allergic bronchopulmonary aspergillosis: Itraconazole
200mg PO bid x 16 weeks or longer.
DOT: 5-10d
3-6 weeks
Preferred Regimen:
1st line: Ciprofloxacin 500mg PO or 400mg IV bid OR
Levofloxacin 500-750 mg IV/PO qd
If enterococcus is suspected/documented:
Ampicillin 1-2g IV q4h; Vancomycin 15mg/kg q12 h
2nd line: TMP-SMX DS bid OR Piperacillin-tazobactam 4.5g IV q6-8h
DOT: 2 weeks; extend to 4 weeks if patient still symptomatic.
P: Co-amoxiclav x 10-14d
Cefuroxime 30mg/kg/d div q12h x min 10d
Type 2: Cefuroxime30mg/kg/d div q12h x min 10d
A: Co-amoxiclav x 10-14d high dose Amoxicillin 1g po tid OR Co-
amoxiclav 875mg/125mg PO q12h x 5-7d
Doxycycline 100mg bid x 5-7d
For patients with severe penicillin allergy (adult):
Type 1: Doxycycline 100mg q12h PO x 5-7d
Type 2: Cefuroxime 500mg bid x 5-7d
Linezolid 600mg IV/PO bid. Give IV until afebrile.
Stepdown to Penicillin VK 500mg PO qid ac and hs (outpatient) x 10d of
total therapy.
history of Penicillin skin rash and nothing to suggest an IgE-mediated
reaction (anaphylaxis, angio-neurotic edema): Cephalexin 500mg PO bid
x 10d
If documented past history of IgE-medicated allergic reaction to beta-
lactam antibiotics: Azithromycin 500mg PO x 1 dose then 250mg PO qd x
4d OR Linezolid 600 mg PO bid x 10d
ACUTE DIARRHEA IN CHILDREN
ACUTE DIFFUSE OTITIS EXTERNA /
SWIMMER’S EAR
ACUTE EPIGLOTTITIS
ACUTE GINGIVITIS
ACUTE NECROTIZING ULCERATIVE
GINGIVITIS
ACUTE OTITIS MEDIA (AOM)
ACUTE OTITIS MEDIA (CLINICAL FAILURE
AFTER 3 DAYS)
ACUTE PANCREATITIS
ACUTE RETINAL NECROSIS
ACUTE RHEUMATIC FEVER
ACUTE SINUSITIS (CLINICAL FAILURE
AFTER 3 DAYS) IN ADULTS
ACUTE UNCOMPLICATED
PYELONEPHRITIS
ACUTE UNCOMPLICATED UTI IN
CHILDREN
ANTICANDIDAL PROPHYLAXIS
3-14d
P: Ofloxacin ear drops
< 1y: no recommendation
1-12y: 5 drops twice a day in the affected ear
> 12y: 10 drops twice a day
DOT: 7-10d or 3d after cessation of symptoms.
A: Ofloxacin ear drops 10 drops 1-2x/d x 7d
P: 1st line: Ceftriaxone 50-100 mg/kg/d q12-24h IV x 7-10d
2nd line: Ampicillin-Sulbactam 100 mg/kg/d q6h IV x 10d
A: 1st line: Ceftriaxone 2g q24h IV infusion x 7-10d
2nd line: Levofloxacin 750mg IV q24h PLUS
Clindamycin 600-900mg q6-8h IV x 7-10d
7-10d, if systemic antibiotics are necessary
10d
P: Amoxicillin 80-90mg/kg/d PO div q12h DOT: <2y: 10 d; 2-5y: 7 d; >5y:
5-7d
Cefuroxime axetil 30mg/kg/d q12h DOT: <2y: 10 d; 2-5y: 7 d; >5y: 5-7d
OR Ceftriaxone 50mg/kg/d IM/IV x 3d
Co-amoxiclav and Ceftriaxone may be used as a first-line agent if at the
onset, the child presents with high fever >39oC and/or if with severe
otalgia.
A: Amoxicillin 1g q8h x 10 d (high dose)
No penicillin allergy Co-amoxiclav 875mg/125mg PO q12h x 10d With
penicillin allergy With anaphylaxis: Levofloxacin 750mg PO q24h x 5d No
anaphylaxis: Cefuroxime axetil 500mg–1g/d PO q12h x 7d OR Ceftriaxone
2g qd IV/IM x 3d
Co-amoxiclav for ≥3 months and <40 kg: 90mg/kg/d q12h using 600/42.9
mg;
DOT: <2yrs: 10 d; >2 y: 5-7d OR
Cefuroxime 30mg/kg/d PO q12h; DOT: <2y OR severe symptoms
regardless of age: 10d; >2yrs with mild or moderate disease:5-7d OR
Ceftriaxone 50mg/kg/d IM x 3d
2nd line:
Mild penicillin allergy: Cefuroxime 15mg/kg/d div q12h or
Ceftriaxone 50mg/kg IM/IV x 3d
Severe penicillin allergy: Levofloxacin 750mg PO bid x 5d
7-14 days depending on clinical response
7–10d
7-10d
1st line or mild/moderate disease: Cefuroxime axetil 500mg q12h PO x 7-
10d
2nd line or severe disease: Levofloxacin 750mg qd PO x 5 d
1st line: Ciprofloxacin 500mg bid x 7-10d OR Levofloxacin 750mg qd x 5d
2nd line: Cefuroxime 500 mg bid x 14d OR Cefixime 400 mg qd x 14d OR
Amoxicillin-clavulanate 625 mg tid x 14d (when GS shows Gram+ cocci)
DOT: 7-14 days
DOT: until recovery of neutropenia
ASYMPTOMATIC BACTERIURIA (ASB)
ASYMPTOMATIC BACTERIURIA (ASB) IN
PREGNANCY
BACTERIAL (NON-GONOCOCCAL)
CONJUNCTIVITIS
BACTERIAL PURULENT PERICARDITIS
BILIARY COMPLICATED INTRA-
ABDOMINAL INFECTIONS
BITE WOUND FROM CAT
BLEPHARITIS
BRAIN ABSCESS
BRONCHIOLITIS/WHEEZY BRONCHITIS
(EXPIRATORY WHEEZING)
BUCCAL CELLULITIS
CAPD-ASSOCIATED PERITONITIS
CAT SCRATCH DISEASE
CATHETER-ASSOCIATED UTI (CAUTI)
CELLULITIS (NON-PURULENT)
CELLULITIS (PURULENT)
CELLULITIS DIABETES MELLITUS AND
ERYSIPELAS
CENTRAL LINE-ASSOCIATED
BLOODSTREAM INFECTION (CLABSI) IN
CHILDREN
CHLAMYDIAL INFECTIONS
CHRONIC BACTERIAL PROSTATITIS (CBP)
When indicated, treatment should be culture-guided. A 7-day regimen is
recommended.
Cefalexin 500mg qid x 7d
Cefuroxime 500mg bid x 7d
Nitrofurantoin macrocrystals 100mg qid x 7d
Fosfomycin 3g single-dose sachet
Amoxicillin-clavulanate 625mg bid x 7d
5-7d
3-4 weeks
10-14d but the primary basis for DOT is the patient’s clinical course.
Preemptive early antimicrobial therapy for 3-5 days is recommended for
patients who are immunocompromised; are asplenic; have advanced
liver disease; have preexisting or resultant edema of the affected area;
have moderate to severe injuries, especially to the hand or face; or have
injuries that may have penetrated the periosteum or joint capsule
Topical antibiotic steroid combination during the acute phase for around
2 to 4 weeks. Antibiotic alone to prevent recurrences for 3 to 6 months.
unclear, usually 6-8 weeks.
P: Ribavirin for severe disease (e.g., requiring mechanical ventilation).
Administer at a concentration of 20mg/mL in sterile water by small
particle aerosol generator (SPAG) 2 via continuous aerosol administration
for over 18-20 hours daily for 3-5d.
7-14d
DOT: generally, 10d but the primary basis for DOT is the patient’s clinical
course.
DOT: 7-10d
Complete resolution may take 2-6 months.
DOT: 7 days w/ prompt resolution of signs and symptoms; 10-14 days of
antibiotic treatment for patients with delayed response
DOT: 7-10d is recommended but should be individualized on the basis of
the patient’s clinical response.
DOT: 7-10d is recommended but should be individualized on the basis of
the patient’s clinical response
Early or mild infection:
Clindamycin 300-450mg (higher dose in obese patient, BMI >40) PO tid x
5-10d
A shorter 5- to 7-day treatment course is reasonable for CLABSI due to
coagulase-negative staphylococci if the catheter is removed and blood
cultures clear promptly.
Usual DOT is 2 weeks
PEDIATRICS <45 kg:
Erythromycin 50mg/kg/d q6h x14d
Pregnant Women:
Erythromycin base 250mg PO qid x 14d OR Erythromycin ethylsuccinate
800mg PO qid x 7d OR Erythromycin ethylsuccinate 400mg PO qid x 14d
Preferred Regimen:

CHRONIC OSTEOMYELITIS
CHRONIC SUPPURATIVE OTITIS MEDIA
(CSOM)
CLINICAL SEPSIS WITHOUT FOCUS
COMMUNITY ACUTE BACTERIAL
MENINGITIS
COMMUNITY-ACQUIRED PNEUMONIA
(CAP) IN ADULTS
COMMUNITY-ACQUIRED PNEUMONIA
(CAP) IN INFANTS AND CHILDREN UP TO 5
YEARS
COMPLICATED ABP
COMPLICATED UTI
CONGENITAL SYPHILIS
CONJUNCTIVITIS OF THE NEWBORN BY
DAY OF ONSET POST-DELIVERY
CRYPTOCOCCAL MENINGITIS (NON-AIDS)
1st line: Ciprofloxacin 400 mg IV q12h OR Levofloxacin 750 mg IV q24h
2nd line: TMP-SMX DS bid
DOT: 4-6 weeks
Optimal DOT: unknown. Prolonged course of therapy is typically
recommended but 6 weeks may be adequate if surgical debridement is
performed. Consider intermittent therapy or chronic suppressive therapy
for relapses if surgical debridement was unsuccessful or not feasible.
Give quinolone ear drops tid for 5 days.
10-14d or longer depending on established foci of infection
DOT (regardless of age):
S. pneumoniae: 10-14d; H. influenzae B: 7-10d; N. meningitidis: 7d;
Culture negative: 10-14d; L. monocytogenes: 21d; Gram-negative enteric
bacilli: 21d
DOT: For S. pneumoniae: 5-7d or 3-5d if using Azithromycin
DOT: 7-10d may be adequate (or 3-5d for azalides). A longer duration of
up to 28d may be given for S. aureus or P. aeruginosa if with concomitant
bacteremia.
PCAP A or B:
If with complete Hib vaccination: Amoxicillin 80-90mg/kg/d div q12h PO
x 5d
If allergic to Amoxicillin, consider macrolide:
Azithromycin 10mg/kg qd PO x 3d or 10mg/kg/d PO on d1 then
5mg/kg/d PO on d2-5 OR Clarithromycin 15mg/kg/d div PO q12h x 7d
Erythromycin 50mg/kg/d PO div q6-8h x 10-14d OR Clarithromycin
suspension 15mg/kg/d div q12h x 10d OR Azithromycin 10mg/kg PO qd x
3d or 10 mg/kg/d PO on d1 then 5mg/kg/d PO on d2-5
DOT: 7 to 10 days for uncomplicated pneumonia, longer courses of 2 to 3
weeks may be required for more severe disease
Preferred Regimen:
1st line: Ciprofloxacin 400 mg IV q12h OR Levofloxacin 750 mg IV q24h
2nd line: Ceftriaxone 1-2g IV q24h PLUS Levofloxacin 750 mg IV q24h OR
Ertapenem 1g IV q24h OR Piperacillin-tazobactam 4.5g IV q8 h
DOT: 4 weeks
DOT: 7-14d
Aqueous crystalline penicillin G 100,000–150,000 U/kg/d, administered
as 50,000 U/kg/ dose IV q12h during the first 7 days of life and q8h
thereafter for a total of 10 – 15d OR Procaine penicillin G 50,000 U/
kg/dose IM x 1 dose for 10-15d
Possible Congenital Syphilis:
Aqueous crystalline penicillin G 100,000–150,000 U/kg/d, administered
as 50,000 U/kg/ dose IV q12h during the first 7d of life and q8h
thereafter for a total of 10d OR Procaine penicillin G 50,000 U/ kg/dose
IM x 1 dose for 10d
3-14d depending on clinical response
Induction Phase DOT: until patient is afebrile and cultures are negative
(approximately 6 weeks)

CRYPTOCOCCAL MENINGITIS ASSOCIATED
WITH HIV/AIDS
CUTANEOUS CANDIDIASIS
DACRYOCYSTITIS (LACRIMAL SAC)
DEEP NECK ABSCESS/ RETROPHARYNGEAL
ABSCESS
DENTOALVEOLAR INFECTION OR PERI-
APICAL ABSCESS
DIABETIC FOOT INFECTIONS (DFI)
DISSEMINATED GONOCOCCAL INFECTION
(DGI) AND GONOCOCCAL SCALP
ABSCESSES IN NEONATES
EMPYEMA
EPIDIDYMITIS
Consolidation phase DOT: 10-12 weeks after CSF culture is negative
Induction Phase DOT: at least 2 weeks
Consolidation phase DOT: at least 8 weeks
Suppression (chronic maintenance therapy) DOT: at least 1 year
1st line: Topical therapy for 3-5d
Clotrimazole 1% cream; Miconazole 2% cream; Ketoconazole 2% cream
applied bid
2nd line: If topical treatment does not work:
Fluconazole 100-200mg PO q week until normal nail anatomy restored
Alternatives: Itraconazole 200mg PO bid x 1 week x 3 consecutive
months OR Terbinafine 250 mg PO od x 3 months
7-14d depending on clinical response
Cefuroxime axetil 20-30mg/kg/d PO q12h PLUS Metronidazole
30mg/kg/d (Max: 4g/d) IV q6h x at least 7d
about 7-14d, until local inflammation has resolved completely.
Mild to moderate DFI:
Clindamycin 300mg PO/IV qid OR Cotrimoxazole 160/800mg 1-2 tabs PO
bid x 1-2 weeks
Severe DFI:
Piperacillin-Tazobactam 4.5g IV q6-8hr IV (for Gram-negative bacilli
coverage, especially if P. aeruginosa is suspected) PLUS Vancomycin (for
MRSA coverage) 15-20mg/kg IV q8-12h x 2-3 weeks
Meropenem 1g IV q8h PLUS Vancomycin 15-20mg/kg IV q8-12h x 2-3
weeks OR Ceftazidime 1-2g IV q8h (or Cefepime) PLUS Metronidazole
500mg IV q8h PLUS Vancomycin 15-20mg/kg IV q8-12h x 2-3 weeks
DOT may be as short as one week for osteomyelitis if all infected and
necrotic bone and soft tissue are resected and there is clinical
improvement. This may be extended for 4-6 weeks (or even longer) if
there is residual infected bone following debridement of necrotic bone.
Ceftriaxone 25–50mg/kg/d IV/IM x 1 dose x 7d OR
Cefotaxime 25mg/kg IV/IM q12h x 7d
if meningitis is documented: DOT: 10-14d
DOT: 2-4 weeks based on clinical response to drainage and antimicrobial
therapy
1st line: All: Bed rest, scrotal elevation, and analgesics.
Age ≤35 years: Ceftriaxone 250mg IM x 1 dose PLUS Doxycycline 100mg
PO bid x 10d (for cases likely caused by chlamydia and gonorrhea)
Add Levofloxacin 500mg PO qd or Ofloxacin 300mg PO bid x 10d if
patient is a man who practices insertive anal sex since he will also be at
risk for enteric organisms, OR give as single agent if no risk for chlamydia
and gonorrhea
Age >35 years: Levofloxacin 750mg IV/PO qd x 10-14d
2nd line:
Age ≤ 35 years: Levofloxacin 500mg PO qd x 10d

ERYSIPELAS
EXTRA-BILIARY COMPLICATED INTRA-
ABDOMINAL INFECTIONS
EXTRA-INTESTINAL INFECTIONS
(BACTEREMIA, MENINGITIS,
OSTEOMYELITIS)
EXUDATIVE OR DIFFUSE ERYTHEMATOUS
PHARYNGITIS OR TONSILLITIS
FEBRILE NEUTROPENIA IN ADULTS (HIGH
RISK)
FEBRILE NEUTROPENIA IN ADULTS (LOW
RISK)
FOLLICULITIS
FUNGAL MENINGITIS
FUNGAL OTITIS EXTERNA / OTOMYCOSIS
FURUNCULOSIS, RECURRENT
GALLBLADDER INFECTION
GASTROENTERITIS (INFECTIOUS
DIARRHEA) IN ADULTS
GENITAL HSV INFECTIONS
GENITAL HSV INFECTIONS SEVERE
DISEASE
GONOCOCCAL CONJUNCTIVITIS
GONOCOCCAL PHARYNGITIS
Age > 35 years: Ampicillin-sulbactam 3g IV q6h OR Ceftriaxone 2g IV q24h
OR Piperacillin-tazobactam 4.5g IV q6h or 4-hr infusion of 2.25g q8h
If penicillin allergic:
DOT: 7-10 days or until the patient is afebrile for 3-5 days; 5 days for
Azithromycin
For erysipelas involving the face:
DOT: 7-10 days, longer if patient is bacteremic
Antimicrobial therapy of established infection should be limited to 4–7
days, unless it is difficult to achieve adequate source control. Longer
durations of therapy have not been associated with improved outcome.
(IDSA Complicated Intra-abdominal Infection Guidelines, CID 2010:50)
Ceftriaxone 100 mg/kg/d IV q12-24h DOT: Bacteremia: 10-14d;
Meningitis: 4 weeks; Osteomyelitis: 4-6 weeks
3-10d
DOT should be dictated by particular organism and site:
Staphylococcus bacteremia should be treated for at least 2 weeks after
negative blood culture; prolonged (4-6 weeks) if disseminated or deep
infection. Other infections may be treated for 14 days.
PLUS Antifungal treatment if fever continues beyond 4-7d and no source
is identified
DOT: Until patient is afebrile and absolute neutrophil count >500cells/μl
DOT: 7-10 days
several weeks until resolution of CSF, radiographic and clinical
abnormalities
P: Clotrimazole 1% solution 2-3 drops q8-12h up to 10-14d OR Gentian
violet may be used and is well tolerated (as recommended by the WHO
Integrated Management of Childhood Illness [IMCI] guidelines).
A: Clotrimazole 1% solution 2-3 drops q8- 12h up to 10-14d
Mupirocin ointment in anterior nares and under fingernails bid x 5-7d
PLUS Chlorhexidine 4% shower qd x 5-7d
14-21d
3-10d
Aciclovir 400mg PO bid x 7-10d OR Aciclovir 200mg PO 5x/d x 7-10d OR
Valaciclovir 1g PO bid x 7-10d OR Famciclovir 250mg PO tid x 7-10d
For children < 45 kg:
Aciclovir 80mg/kg/d PO div q6-8h (Max: 1.2g/day) x 7-10d
Valaciclovir 40mg/kg/d div q12h x 7-10d
Comments: Diagnosis: Viral culture, PCR, HSV serology. Extend treatment
if healing is incomplete after 10 days.
Preferred Regimen: Aciclovir 5–10mg/kg IV q8h x 2-7d or until clinical
improvement is observed, followed by oral antiviral therapy to complete
at least 10 days.
Comments: HSV encephalitis requires 21 days of intravenous therapy.
Impaired renal function warrants dose adjustment.
2-3 weeks
P: Ceftriaxone
<45 kg: 125mg IM x 1 dose;

GRANULOMA INGUINALE
(DONOVANOSIS)
GRANULOMATOUS MASTITIS DUE TO
CORYNEBACTERIUM SP
HERPES KERATITIS
HERPES NEONATAL
HERPES SIMPLEX
HERPES SIMPLEX VIRUS
GINGIVOSTOMATITIS
HERPES ZOSTER, SHINGLES
HIGH-RISK CAP
HOSPITAL-ACQUIRED PNEUMONIA (HAP)
AND VENTILATOR-ASSOCIATED
PNEUMONIA (VAP) IN ADULTS
>45 kg: 250mg IM x 1 dose
A: Ceftriaxone 250mg IM x 1 dose
Azithromycin 1g PO q week OR 500 mg qd for at least 3 weeks and until
all lesions have completely healed
Doxycycline 100mg PO bid for at least 3 weeks and until all lesions have
completely healed OR
Ciprofloxacin 750mg PO bid orally for at least 3 weeks and until all
lesions have completely healed OR
Erythromycin base 500mg PO qid for at least 3 weeks and until all lesions
have completely healed OR
Trimethoprim-sulfamethoxazole one double-strength (160 mg/800mg)
tablet PO bid for at least 3 weeks and until all lesions have completely
healed.
Doxycycline 100mg PO bid x 3-4 weeks
7d
Preferred Regimen: Aciclovir 20mg/kg IV q8h x 14d if disease is limited to
the skin and mucous membranes, or for 21 days for disseminated disease
and involving the central nervous system.
14-21 days
7d
Immunocompetent: Aciclovir 800mg PO 5x/d x 7-10d PLUS Prednisone in
patients age >50 yrs. to decrease discomfort during acute phase of
infection. Does not decrease incidence of post-herpetic neuralgia. Day 1-
7: 30mg PO bid Day 8-14: 15mg PO bid Day 15-21: 7.5mg PO bid
Immunocompromised: Not severe: Aciclovir 800mg PO 5x/d x 7d Severe
(>1 dermatome, trigeminal nerve or disseminated): Aciclovir 10-12mg/kg
IV (infusion over 1hr) q8h x 7-14d
Immunocompetent: Valaciclovir 1g PO tid x 7d
Immunocompromised (not severe): Valaciclovir 1g PO tid x 7d
7-10 days may be adequate. A longer duration of up to 28 days may be
given for S. aureus or P. aeruginosa if with concomitant bacteremia.
DOT: 7 days may be longer depending on clinical radiologic and
laboratory improvement
Burkholderia pseudomallei
P:1st line: Ceftazidime 150 mg/kg/d IV div q8h OR Meropenem
60mg/kg/d div IV q8h x 7-14d PLUS Cotrimoxazole 8 mg/kg/d PO div
q12h (TMP component) x 12-24 weeks.
Some eradication regimens use:
Amoxicillin-clavulanate 90 mg/kg/d PO div q8h (amoxicillin component)
OR
Doxycycline 4mg/kg/d div q12h PLUS Cotrimoxazole 8 mg/kg/d PO div
q12h (TMP component) x 12-24 weeks
A:1st line: Ceftazidime 2g IV q6h x 10-14d OR Meropenem 1g IV q8h x 10-
14 d
 Followed by oral therapy: Cotrimoxazole 6-8mg/kg bid (TMP component)
plus Folic acid 5mg qd OR Doxycycline 100mg bid OR Amoxicillin-
clavulanate 625mg PO tid (for pregnant or sulfa allergy)
DOT: 6 months for osteomyelitis and CNS infection, 3 months for other
infections
HUMAN BITE Early (wound not yet infected):
Amoxicillin-Clavulanate 875/125 mg PO bid x 5d
Later (signs of infection, usually 3-24 h):
Ampicillin-Sulbactam 1.5 to 3 g IV q6h OR Piperacillin-Tazobactam (4.5 g
q8h or 4-hr infusion of 3.375 g q8h).
For serious infections, until MRSA is excluded: ADD Vancomycin 1g IV
q12h (or 1.5g q12h if wt. >100 kg)

DOT: 5 days
IMPETIGO AND ECTHYMA Streptococcus sp.
Mupirocin ointment 2% tid OR
Fusidic acid 2% cream bid
DOT: 7-12d

Methicillin-susceptible Staphylococcus aureus bullous impetigo:

Cloxacillin 50-100mg/k/d in 4 doses (Max: 12 g/d) OR Cephalexin Mild to
moderate infections: 25-50 mg/kg/d in 3-4 doses Severe infections: 75-
100mg/kg/d in 3-4 doses (Max: 4 g/d)
DOT: 7d
Suspected or confirmed methicillin-resistant Staphylococcus aureus
bullous impetigo:
Clindamycin 30-40mg/k/d in 3-4 doses (Max: 1.8 g/d) OR Cotrimoxazole
8-12mg/kg/d in 2 doses (TMP component) (Max: 320mg/d) OR
Doxycycline 2-4mg/kg/d in 1-2 doses (Max: 200mg/d) DOT: 7d
INFECTIVE ENDOCARDITIS 2-4 weeks
INFLUENZA P: Oseltamivir
Infant 2 weeks-11 months: 3mg/kg bid x 5d
≤15kg: 30mg bid x 5d
>15kg to 23kg: 45mg bid x 5d
>23kg to 40kg: 60mg bid x 5d
>40kg: 75mg bid x 5d
A: Oseltamivir 75mg PO bid x 5d
INTRA-ABDOMINAL SOURCE 10-14d or longer depending on established foci of infection

JUVENILE PERIODONTITIS 7d
LEPROSY PEDIA Multibacillary (MB) Regimen (10-14 years old)
Monthly Treatment: Day 1
 Rifampicin 450 mg
 Clofazimine 150 mg
 Dapsone 50 mg

Daily Treatment: Days 2-28

 Clofazimine 50 mg qod
 Dapsone 50 mg

DOT: 12 blister packs to be taken monthly within a maximum period of

18 months.
 *Note: Lapses in taking MDT should be <3 months

ADULT (MB) Regimen (15 years old and above)

Monthly Treatment: Day 1
 Rifampicin 600 mg
 Clofazimine 300 mg
 Dapsone 100 mg

Daily Treatment: Days 2-28

 Clofazimine 50 mg
 Dapsone 100 mg

DOT: 12 blister packs to be taken monthly within a maximum period of

18 months.
*Note: Lapses in taking MDT should be <3 months

CHILD PB Regimen (10-14 years old)

Monthly Treatment: Day 1
 Rifampicin 450 mg
 Dapsone 50 mg

Daily Treatment: Days 2-28

 Dapsone 50 mg

DOT: 6 blister packs to be taken monthly within a maximum period of 9

months
*Note: Lapses in taking MDT should be < 1 month

ADULT PB Regimen (15 years old and above)

Monthly Treatment: Day 1
 Rifampicin 450 mg
 Dapsone 50 mg

Daily Treatment: Days 2-28

 Dapsone 50 mg

DOT: 6 blister packs to be taken monthly within a maximum period of 9

months
*Note: Lapses in taking MDT should be < 1 month
LIVER ABSCESS 4-6 weeks
LUDWIG’S ANGINA 2-3 weeks until clear evidence of clinical improvement is present, and
fever and leukocytosis have disappeared. If complications arise, longer
courses may be necessary.
LUNG ABSCESS DOT: 4-6 weeks.
LYMPHOGRANULOMA VENEREUM 1st line: Doxycycline 100mg PO bid x 21d
2nd line: Erythromycin base 500mg PO qid x 21d
MEMBRANOUS PHARYNGITIS DUE TO P: Phenoxymethylpenicillin 25-50mg/kg/d PO q6h x 14d
DIPHTHERIA A: Phenoxymethylpenicillin 250mg PO q6h x 14d
MILD LEPTOSPIROSIS <8 yo: Amoxicillin 50mg/kg q8h x 7d
≥8 yo: Doxycycline 2-4mg/kg/d bid x 7d
Azithromycin 1g loading dose then 10 mg/kg qd x 2d
MIXED INFECTIONS
MODERATE TO SEVERE LEPTOSPIROSIS
MONOARTICULAR ACUTE BACTERIAL
ARTHRITIS
NECROTIZING FASCIITIS/GAS GANGRENE
NECROTIZING OTITIS EXTERNA
NEONATAL SEPSIS (IMCI AND DOH
CRITERIA)
NEUROSYPHILIS
NONTYPHOIDAL SALMONELLOSIS
ORAL CANDIDIASIS
ORBITAL CELLULITIS IN ADULTS
ORBITAL CELLULITIS IN CHILDREN
OSTEOMYELITIS
OSTEOMYELITIS, CONTIGUOUS FOCUS
OSTEOMYELITIS (CHRONIC)
OSTEOMYELITIS (CONTIGUOUS WITH
VASCULAR INSUFFICIENCY
OSTEOMYELITIS (CONTIGUOUS WITHOUT
VASCULAR INSUFFICIENCY) FOOT BONE
(CALCANEUS) FOLLOWING PUNCTURE
WOUND
OSTEOMYELITIS (HEMATOGENOUS) LONG
BONES
OSTEOMYELITIS (HEMATOGENOUS)
VERTEBRAL, INCLUDING DISC SPACE
INFECTIONS AND OTHER SITES
<35 kg:3 tabs on d1 and 8 h after, 3 tabs bid on d2-3 > 35 kg: 4 tabs on
day 1 and 8 h after, 4 tabs bid on d2-3
PLUS Primaquine
Post-partum/lactating women: 0.25 mg/kg/day on days 1-14
Penicillin 250,000-400,000 U q4-6h x 7d
Ampicillin 100 mg/kg q6h x 7d
Cefotaxime 100-150 mg/kg q6-8h x 7d
Ceftriaxone 80-100 mg/kg q24h x 7d
Azithromycin 500mg qd x 5d
2-4 weeks
DOT: 10d
P: 1st line: Ceftazidime 100-150mg/kg/d IV q8h
2nd line: Piperacillin-tazobactam 300mg/kg/d IV q8h
A: 1st line: Piperacillin-tazobactam 4.5g IV q6h
2nd line: Piperacillin-tazobactam 4.5g IV q6h +/- Gentamicin or Amikacin
qd
DOT is 6 weeks and until clinical and radiographical improvement has
been achieved.
7-10d or approximately 5-7d after clinical signs and symptoms of
infection have disappeared
Aqueous crystalline penicillin G 18–24 MU/d, administered as 3–4 MU IV
q4h or continuous infusion x 10-14d
Cefotaxime 100-200 mg/kg/d IV q6h x 5-14d
Ceftriaxone 75 mg/kg/d IV q24h x7d
Cefixime 15 mg/kg/d PO q12h x 7-10d
Ciprofloxacin 10-20 mg/kg/d q12h x 7-10d
Chloramphenicol 50-75 mg/kg/d q6h x 7d
7-14d
10-21 days depending on clinical response; 4-6 weeks if bone changes
are suggestive of osteomyelitis
7-14 days depending on clinical response
DOT for neonates is not well-defined but 3 weeks is considered
adequate. DOT for other age groups is 3-6 weeks.
DOT: not well defined but 6 weeks is generally recommended, longer if
hardware retained.
The optimal treatment duration and route is uncertain; antibiotic
treatment is usually prolonged (usually 6 weeks).
DOT (IV to oral): Approximately 6 weeks from the last debridement
Onset within 30d: early debridement, retention of implant, and definitive
antibiotic x 3 months
Late-onset (>30d): implant removal, debridement, and definitive
antibiotic x 6 weeks
DOT: 4-6 weeks
Optimal DOT is unknown; usually 6-12 weeks.
OTITIS EXTERNA
PARAPHARYNGEAL SPACE INFECTION;
PERITONSILLAR ABSCESS
PATHOGEN-SPECIFIC TREATMENT
S. VIRIDANS OR S. BOVIS (S.
GALLOLYTICUS)
PELVIC INFLAMMATORY DISEASE
N. GONORRHOEAE; C. TRACHOMATIS;
BACTEROIDES; ENTEROBACTERIACEAE; G.
VAGINALIS; H. INFLUENZAE; ENTERIC
GRAM-NEGATIVE RODS; S. AGALACTIAE;
CYTOMEGALOVIRUS (CMV); M. HOMINIS;
U. UREALYTICUM; M. GENITALIUM
PERICORONITIS
PERIHEPATITIS OR FITZ-HUGH-CURTIS
SYNDROME
PERIODONTAL ABSCESS
P: Ofloxacin ear drops
< 1y: no recommendation
1-12y: 5 drops bid in the affected ear
> 12y: 10 drops bid
DOT: 7-10d or 3d after cessation of symptoms.
A: Ofloxacin ear drops 10 drops/d x 7d
P: Co-amoxiclav 40mg/kg/d PO div q8h x 10d
A: Metronidazole 500mg IV q8h x at least 7d
4 weeks (Pedia)
2-4 weeks (Adult)
4 weeks if symptoms <3 months; 6 weeks if symptoms >3 months
P: 1st line:
Cefoxitin 2g IV q6 PLUS
Doxycycline 100mg PO q12h x 14d
OR
Clindamycin 900mg IV q8h PLUS Gentamicin 2mg/kg IV/IM loading dose,
followed by 1.5mg/kg q8h maintenance dose. Single daily dosing (3–
5mg/kg) can be used
THEN Doxycycline 100mg PO q12h x 14d
2nd line:
Ampicillin-sulbactam 3g IV q6h PLUS Doxycycline 100mg PO q12h x 14d
A: Ceftriaxone 250mg IM/IV x 1 dose
OR Cefotaxime 0.5-1.0g IM x 1 dose PLUS Doxycycline 100mg PO bid x
14d
WITH or WITHOUT
Metronidazole 500mg PO bid x 14d
7d
PARENTERAL REGIMEN
1st line:
Cefoxitin 2g IV q6h PLUS
Doxycycline 100mg PO q12h x 14d
WITH or WITHOUT
Metronidazole 500mg PO bid x 14d
OR
Clindamycin 900mg IV q8h PLUS
Gentamicin 2mg/kg IV/IM loading dose, followed by 1.5 mg/kg q8h
maintenance dose. Single daily dosing (3–5 mg/kg) can be used.
Continuing oral therapy should consist of:
Doxycycline 100mg PO bid x 14d
OR Clindamycin 450mg PO qid x 14d
2nd line:
Ampicillin-sulbactam 3g IV q6h PLUS Doxycycline 100mg PO q12h x 14d
OUTPATIENT REGIMEN
Ceftriaxone 250mg IM once OR
Cefotaxime PLUS
Doxycycline 100mg PO bid x 14d
WITH or WITHOUT
Metronidazole 500mg PO bid x 14d
7d
PERITONSILLAR ABSCESS (QUINSY)
PERITONSILLAR ABSCESS (QUINSY)
PERSISTENT COUGH (>14 DAYS), AFEBRILE
DURING COMMUNITY OUTBREAK:
PLASMODIUM FALCIPARUM AND P.
VIVAX WITH/ WITHOUT P. MALARIAE
PLASMODIUM OVALE
PLASMODIUM VIVAX ACUTE
PLASMODIUM VIVAX AND P. MALARIAE
PLASMODIUM VIVAX OR P. OVALE
10d
P: Neonates younger than 1 month:
Azithromycin 10mg/kg/d q24h for 5d
Erythromycin 40mg/kg/d in 4 div doses x 14d
>2 mos.:
Azithromycin 10mg/kg/d PO on d1 then 5mg/kg/d PO q24h x 4d OR
Clarithromycin 7.5mg/kg PO q12h x 7d
(Max: 1g/d) OR
Erythromycin estolate 40mg/kg/d in 4 div doses OR
Erythromycin base 40mg/kg/d div q6h x 7-14d (Max: 1-2g/d) OR
Trimethoprim-sulfamethoxazole 8/40mg/kg/d in 2 div doses/d x 14d
A: Azithromycin 500mg PO on d1, 250mg q24h on d2-5
OR
Erythromycin estolate 500mg PO qid x14d OR
Trimethoprim-sulfamethoxazole 160/800mg PO bid x 14d
OR
Clarithromycin 500mg PO bid x 7d
Pertussis prophylaxis of household contacts (adults and children):
Azithromycin 500mg PO x1 dose on d1, then 250mg q24h on d2–5 OR
Erythromycin 500mg PO qid 14d OR
Clarithromycin 500mg PO bid x 7d OR
Trimethoprim-sulfamethoxazole 160/800 mg 1 tablet PO bid x 14d
P: Artemether–Lumefantrine (20 mg/120 mg) combination
PLUS Primaquine tablet 0.25 mg-base/kg starting on days 1-14 (pediatric
and adult) A: Artemether–Lumefantrine (20mg/120mg) combination on
d1, 4 tabs followed by 4 tabs after 8h, then 4 tabs bid for d2-3 PLUS
Primaquine tablet 0.25mg-base/kg starting on d1-14 (pediatric and adult)
PREGNANT: Chloroquine tab 10mg/kg on d1-2, and 0.5 mg/kg on d3
LACTATING: ADD Primaquine 0.25mg/kg body weight per day beginning
day 1 to 14 to the above regimen.
Comments:
Withhold primaquine during the entire period of pregnancy, but give it 2
weeks after delivery at 0.5 mg/kg/day for 14 days.
Withhold primaquine during the entire period of pregnancy, but give it 2
weeks after delivery at 0.25 mg/kg/day for 14 days.
P and A: Chloroquine tablet 10 mg/kg on d1-2, then 5 mg/kg body weight
on d3 PLUS Primaquine 0.25 mg base/kg/d (taken as a single dose) for
d1-14
1st line: Chloroquine 10mg/kg on d1-2, then 5mg/kg on d3 (pediatric and
adult) PLUS
Primaquine 0.25mg base/kg/day x1 dose for d1-14 (pediatric and adult)
2nd line:
P: Artemether–lumefantrine (20mg/120 mg) combination

PLASMODIUM VIVAX RELAPSE
PNEUMONIA, ANAEROBIC OR
ASPIRATION WITH OR WITHOUT LUNG
ABSCESS
POLYARTICULAR ACUTE BACTERIAL
ARTHRITIS
POTENTIALLY SEPTIC NEONATE
(ASYMPTOMATIC NEONATES WITH
DOCUMENTED MATERNAL RISK FACTORS
LIKE HISTORY OF UTI DURING THE LAST
TRIMESTER, MEMBRANES RUPTURED
>18H BEFORE DELIVERY, FEVER >38°C
BEFORE DELIVERY OR DURING LABOR
AND/OR FOUL-SMELLING OR PURULENT
AMNIOTIC FLUID)
PRIMARY SPONTANEOUS BACTERIAL
PERITONITIS (SBP)
PROSTHETIC JOINT INFECTIONS
PROSTHETIC VALVE
PURULENT CELLULITIS
PYELONEPHRITIS
PYOMYOSITIS
PLUS Primaquine tablet 0.25mg-base/kg starting on d1 (pediatric and
adult)
A: Artemether–Lumefantrine (20mg/120mg) combination on d1, 4 tabs
followed by 4 tabs after 8h, then 4 tabs bid for d2-3 PLUS Primaquine
tablet 0.25mg-base/kg on d1-14 (pediatric and adult)
Primaquine should be taken with meals (causes abdominal discomfort
taken on an empty stomach). Do not give primaquine to patients with
G6PD-deficiency. Patients with mild deficiency may receive a dose of
0.75 mg/kg once a week for 8 weeks.
PREGNANT: Chloroquine 150mg base/tab 2 tabs per week for 8 weeks
LACTATING: ADD Primaquine 0.25mg/kg body weight per day (mmax:30-
45 mg/ day) beginning d1-14 to the above regimen
Comments:
Withhold primaquine during the entire period of pregnancy, but give it 2
weeks after delivery at 0.5-0.75 mg/kg/ day (maximum of 30-45 mg/d)
for 14 days.
DOT: Up to 3-4 weeks, depending on clinical response; longer (up to 2-3
months) for lung abscess
2-4 weeks
For infants who remain asymptomatic and whose initial blood cultures
are negative after 48-72 hours of incubation, antimicrobial therapy can
be discontinued. If no pathogen has been isolated but bacterial sepsis
cannot be excluded, a negative CRP test at 72 hours can help support
decision to discontinue antibiotics.
Pediatrics DOT: 10d-3 weeks
DOT: Unclear. Treat at 5 days and perhaps longer if documented
bacteremia
4-6 weeks
(6 months for total knee arthroplasty)
6 weeks
Non-severe:
Clindamycin 300-450mg (higher dose in obese patient, BMI >40) PO tid x
5-10d OR Cotrimoxazole 160/800mg (1 DS tab; 2 DS tabs in obese
patient, BMI >40) PO bid x 5-10d OR Doxycycline 100mg PO q12h x 5-10d
may also be effective for community acquired MRSA infections
Preferred Regimen:
Fluconazole 200 mg PO qd x 2 wks.
For fluconazole-resistant Candida (C. krusei or C. glabrata):
AmB deoxycholate 0.3-0.6 mg/kg x 2 wks.
DOT: 2-3 weeks
RAT BITE
RECURRENT FURUNCULOSIS
RECURRENT PHARYNGITIS
RELAPSE (LABORATORY CONFIRMED)
(RELAPSE REFERS TO RECURRENCE OF
PARASITEMIA DUE TO HYPNOZOITES OF
P. VIVAX)
SCABIES
SCABIES
SEAWATER, BRACKISH WATER-
ASSOCIATED, CONTAMINATED SKIN
WOUNDS
SECONDARY PERITONITIS
SEPTIC BURSITIS
SEVERE SEPSIS AND SEPTIC SHOCK
SEVERE/COMPLICATED TYPHOID FEVER
(PEDIA)
SEVERE/COMPLICATED TYPHOID FEVER
(ADULT)
SKIN ABSCESS, BOILS, FURUNCLES
SKIN ABSCESS, BOILS, FURUNCLES
STAPHYLOCOCCAL SCALDED SKIN
SYNDROME
Prophylaxis: Amoxicillin-clavulanate 875/125mg PO bid
Doxycycline 100mg PO bid x 3d
Prophylaxis DOT: 3d
Rat bite fever:
Penicillin G 2MU IV q4h OR
Doxycycline 100mg PO bid
Erythromycin 500mg PO qid OR
Clindamycin 300mg PO qid x 10-14d
DOT: 10-14d
Mupirocin ointment in anterior nares and under fingernails bid x 7d PLUS
Chlorhexidine 4% shower daily x 7d
10d
Chloroquine 10mg/kg BW for d1-2, and 5 mg/kg BW on d3 OR
Artemether–Lumefantrine for 3 days (see regimen for uncomplicated
vivax malaria) PLUS Primaquine 0.75mg/kg/d on d1-14 (Max: 30–45
mg/d) (do not give if patient is G6PD deficient)
Chloroquine and primaquine-tolerant vivax is known to exist in nearby
countries particularly in East Timor, Indonesia Papua New Guinea,
Myanmar and Thailand. If recurrence of parasitemia is within 28 days
after the start of chloroquine, the patient is treated with AL.
Permethrin 5% cream
Repeat in 1-2 weeks
Permethrin 5% cream applied to all areas of the body from the neck
down and washed off after 8–14h OR Ivermectin 200ug/kg PO, repeated
in 2 weeks
DOT: based on clinical response.
DOT: Antibiotics are generally given for 5-10d but the primary basis for
duration of antibiotic treatment is the patient’s clinical course.
14-21d
10-14d in the absence of a complication
Ceftriaxone 75mg/kg/d IV q24h x 10-14d
Ciprofloxacin 30mg/kg/d q12h x 7-10d
Azithromycin 20mg/kg/d IV q24h x 5-7d
Cefixime 15-20mg/kg q12h x 7-10d
Azithromycin 20mg/kg q24h x 5-7d
Ciprofloxacin 30mg/kg q12h x 7-10d
Ceftriaxone 1-2g IV x 10-14d
Ciprofloxacin 400mg IV q12h x 7-10d
Cefixime 200mg 1tab q12h x 7-10d
Azithromycin 500mg 1-2tabs q24h x 5-7d
Ciprofloxacin 500mg 1tab q12h x 7-10d
DOT: 5-10d
Clindamycin 300-450mg (higher dose in obese patient, BMI>40) PO tid x
5-10d OR Cotrimoxazole 160/800mg (1 DS tab; 2 DS tabs in obese
patient, BMI>40) PO bid x 5-10d OR Doxycycline 100 mg PO q12h x 5-10d
(may also be effective for community-acquired MRSA infections)
DOT: 7-10d for MSSA
STAPHYLOCOCCAL TOXIC SHOCK
SYNDROME
STREPTOCOCCAL TOXIC SHOCK (ADULT)
STREPTOCOCCAL TOXIC SHOCK
SYNDROME (PEDIA)
SUPPURATIVE ARTHRITIS (CHILDREN
AGED 3 MONTHS TO 14 YEARS)
SUPPURATIVE ARTHRITIS (INFANTS <3
MONTHS OLD)
SYMPTOMATIC CYSTITIS
SYPHILIS LATE LATENT
SYPHILIS LATENT (EARLY LATENT
SYPHILIS)
SYPHILIS PRIMARY
SYPHILIS SECONDARY
TINEA CAPITIS (RINGWORM)
TINEA CORPORIS, TINEA CRURIS (JOCK
ITCH), TINEA PEDIS (ATHLETE’S FOOT)
TINEA CORPORIS/CRURIS
TINEA PEDIS
TINEA VERSICOLOR (PITYRIASIS
VERSICOLOR)
10-14d in the absence of a complication
DOT is individualized; Min of 14d if with bacteremia
10-14d or longer depending on established foci of infection
DOT: After initial response, therapy is usually completed with oral
therapy for a total of 2-3 weeks.
DOT for neonates is not well-defined but 3 weeks is considered adequate
Preferred Regimen:
Fluconazole 200-400mg PO qd x 2 weeks
For fluconazole-resistant Candida (C. krusei or glabrata):
AmB deoxycholate 0.3-0.6mg/kg x 1-7d
Doxycycline 100mg PO bid x 30d OR Tetracycline 500mg PO qid x 30d
Doxycycline 100mg PO bid x 14d OR Tetracycline 500mg qid x 14d OR
Ceftriaxone 1g IV/IM q24h x10-14d
Doxycycline 100mg PO bid x 14d OR Tetracycline 500mg qid x 14d OR
Ceftriaxone 1g IV/IM q24h x 10-14d OR Azithromycin 2g PO x 1 dose
ADULTS
Doxycycline 100mg PO bid x 14d OR Tetracycline 500mg qid x 14d OR
Ceftriaxone 1g IV/IM q24h x10-14d
Terbinafine
P (age>2y); weight-based dosing
<20 kg: 62.5mg PO in 1 dose x 2 weeks
20-40 kg: 125mg PO in 1 dose x 2 weeks
>40 kg: 250mg PO in 1 dose x 2 weeks
Itraconazole 5mg/kg/d x 4 weeks
Fluconazole 6mg/kg/d PO every week x 8-12 weeks (Max: 150 mg PO
every week for adults)
Griseofulvin (microsize formulation) 10-20 mg/kg/d (child) until hair
regrows.
Terbinafine 1% cream 2 weeks.
Imidazoles (clotrimazole, ketoconazole, etc.) apply bid x 2-4 weeks
1st line: Terbinafine 1% cream bid x 3-4 weeks (recommended) OR
Ketoconazole 2% cream qd or bid x 2-4 weeks OR
Clotrimazole 1% cream, powder, solution bid x 2-4 weeks
2nd line: Topical therapy ineffective or intolerant to topical medications,
or with extensive and/or disabling, multifocal or inflammatory disease,
deeper infection with hair follicle involvement: Terbinafine 250mg PO qd
x 2-4 weeks OR Itraconazole 200mg PO qd x 2-4 weeks or 200mg bid x 7d
OR Fluconazole 50-100mg PO qd or 150mg once weekly x 2-3 weeks
1st line: Terbinafine 1% cream qd x 2-4 weeks (recommended) OR
Ketoconazole 2% cream bid x 3-6 weeks OR Clotrimazole 1% bid x 2-4
weeks
2nd line: Terbinafine 250mg PO x 2 weeks Fluconazole 150mg PO q1wk x
4 weeks
Limited disease:
Ketoconazole 2% shampoo daily for 3 days; can use 2-3 times a week for
maintenance/prevention
 Selenium sulfide 2.5% shampoo, daily application while bathing for 1 to 2
weeks, can use 2-3 times a week for maintenance/prevention
Extensive disease:
Fluconazole 3-6mg/kg x 1 dose, repeat in 14 days

Itraconazole 5-10mg/kg/d PO in 2 doses x 7d

TUBERCULOSIS (TB)

CATEGORY IA
Etiology: Extra-pulmonary TB (EPTB), New: CNS, bones or joints

CATEGORY II 2HRZES/ 1HRZE/5HRE

Etiology: PTB or EPTB, previously treated drug-susceptible TB (whether
bacteriologically confirmed or clinically diagnosed)
• Relapse
• Treatment After Failure
• Treatment After Lost to Follow-up (TALF)
• Previous Treatment Outcome Unknown
• Other

CATEGORY IIA 2HRZES/ 1HRZE/9HRE

Etiology: EPTB, previously treated drug-susceptible TB (whether
bacteriologically confirmed or clinically diagnosed) - CNS, bones or joints.

Standard Regimen Drug Resistant (SRDR)

Shorter Treatment Regimen: Moxifloxacin-Kanamycin-Prothionamide-

Clofazimine-Pyrazinamide-Ethambutol-Isoniazid high dose
(MfxKmPtoCfzEZH)

TUBO-OVARIAN ABSCESS
TYPHOID CHRONIC CARRIER (ADULT)
TYPHOID CHRONIC CARRIER (PEDIA)
UNCOMPLICATED TYPHOID FEVER
(ADULT)
UNCOMPLICATED TYPHOID FEVER (PEDIA) Amoxicillin 75-100mg/kg/d q8h x 14d
UNCOMPLICATED UTI IN ADULTS
URETHRITIS
URINARY SOURCE (SEE UTI,
COMPLICATED)
UTI, RECURRENT CATHETER RELATED OR
WITH CO-MORBIDS IN CHILDREN
UTI IN PREGNANCY
• Strictly provided to MDR/RR-TB only.
• Treatment duration for 9-11 months.
Conventional Treatment Regimen:
• Provided to patients who do not qualify for the Shorter Treatment
• Treatment duration for 20-24 months.
PARENTERAL REGIMEN
Cefoxitin 2g IV q6h PLUS
Doxycycline 100mg PO q12h x 14d OR
Clindamycin 900mg IV q8h PLUS Gentamicin 2mg/kg IV/IM loading dose,
followed by 1.5 mg/kg q8h maintenance dose. Single daily dosing (3–5
mg/kg) can be substituted PLUS
Doxycycline 100mg PO bid x 14d
OUTPATIENT REGIMEN
Doxycycline 100mg PO bid OR
Clindamycin 450mg PO qid x 14d
DOT (IV/PO): at least 21 days.
Ciprofloxacin 500-750mg q12h PO x 28d
Ciprofloxacin 30mg/kg/d q12h x 4 weeks
Ampicillin 100-200mg/kg/d IV q6h x 4 weeks
Amoxicillin 1g q6h x 14d
TMP-SMX 800/180mg I tab q12h x 14d
Chloramphenicol 1g PO q6h x 14d
Ciprofloxacin 500mg 1 tab q12h x 7-10d
Cefixime 200mg PO q12h x 7- 10d
Azithromycin 500mg-1g PO qd x 5-7d
Ampicillin 100-200mg/kg/d IV q6h x 14d
Chloramphenicol 50-75mg/kg/d q6h x 14-21d
TMP-SMX 8mg/kg/d (TMP component) q12h x 14d
Cefixime 15-20mg/kg/d q12h x 7-10d
Azithromycin 20mg/kg/d q24h x 5-7d
Ciprofloxacin 30mg/kg/d q12h x 7-10d
Cefuroxime 250mg bid x 7d OR
Cefixime 200mg bid x 7d OR
Amoxicillin-clavulanate 625mg bid x 7d
PEDIATRIC
<45kgs and <8years of age:
Ceftriaxone 125mg IM x 1 dose PLUS
Erythromycin base OR ethylsuccinate 50mg/kg/d PO in 4 div doses (Max:
2g/day) x 14d
>45kgs but <8years of age:
Ceftriaxone 250mg IM x 1 dose PLUS
Azithromycin 1g PO x 1 dose
10-14d or longer depending on established foci of infection
DOT: 7-14 days depending on response.
Cefalexin 500mg qid x 7d

VAGINITIS, PREPUBERTAL
VARICELLA ZOSTER OPTHALMICUS
VARICELLA ZOSTER VIRUS
VARICELLA-ZOSTER VIRUS INFECTIONS
VESICULAR, ULCERATIVE PHARYNGITIS
(VIRAL)
VIRAL CONJUNCTIVITIS (PINK EYE)
Cefuroxime 500mg bid x 7d
Cefixime 200mg bid x 7d
Nitrofurantoin macrocrystals 100mg qid x 7d
Fosfomycin 3g single-dose sachet
Amoxicillin-clavulanate 625mg bid x 7d
Oral:
Cefalexin 500mg to complete 14d
Cefuroxime 500mg bid to complete 14d
Cefixime 200mg bid to complete 14d
Amoxicillin-clavulanate 625mg bid to complete 14d
Recommended duration of treatment is 14d
<45kgs, < 8 years of age:
Ceftriaxone 125mg IM x 1 dose PLUS Erythromycin 50mg/kg/d div q6h x
14d
10d
Immunocompetent host, chickenpox:
Aciclovir 800mg PO 5x/d x 5-7d (start within 24h of rash) OR
Valaciclovir 1g PO tid x 5d
Pregnancy (3rd trimester), pneumonia:
Aciclovir 800mg PO 5x/d or 10 mg/kg IV q8h x 5d
Immunocompromised:
Aciclovir 10-12mg/kg (500 mg/M2) IV (infused over 1 hour) q8h x 7d
2nd line: Valaciclovir 1g PO tid x 5d
Aciclovir 80mg/kg/d PO in 4 doses (Max: 3200mg/d) (start within 24h of
rash) OR
Valaciclovir 60mg/kg/d PO in 3 doses (Max: 1g/dose in 3 doses)
DOT: 5 days
For HSV 1 and 2 in immunocompromised host:
P: Aciclovir
Infants and children < 12y: 10mg/kg q8h x 7-14d as 1-3h IV infusion
> 12y: 5 mg/kg q8h x 7-14d as 1-3h IV infusion OR
Valaciclovir 12y: 4g/d q12h x 1d
A: Aciclovir 400mg PO 5x/d x 5d OR Valaciclovir 500mg bid x 7d
Recurrent herpes labialis:
P: Valaciclovir Children > 12 y: 4g/d q12h x 1d
A: Valaciclovir 500mg bid x 7d
7 to 14 days